Method for immunohistochemical detection of endotoxin in hepatocellular carcinoma

Through immunohistochemical detection methods, the problem of endotoxin detection in hepatocellular carcinoma was solved, and quantitative analysis of endotoxins in hepatocellular carcinoma was provided, the foundation for the prognosis of hepatocellular carcinoma was laid, and effective detection of endotoxins in hepatocellular carcinoma was achieved. Prognosis analysis.

CN119001094AInactive Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411104030.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art cannot effectively detect and quantitatively analyze the expression of endotoxins in hepatocellular carcinoma, resulting in a lack of prognostic predictive indicators, affecting the therapeutic effect of hepatocellular carcinoma and patient prognosis.

Method used

Immunohistochemical detection methods are used to block endogenous peroxidase through sectioning treatment, antigen repair, blocking endogenous peroxidase, incubating primary and secondary antibodies, chromatogenesis and quantitative analysis. The specific steps include sectioning, copying, dewaxing, and hydration. , Antigen repair, blocking endogenous peroxidase, incubating primary antibodies, washing primary antibodies, incubating secondary antibodies, chromatogenesis and counterstaining, quantitative analysis was performed using Image J.

Benefits of technology

Quantitative detection of endotoxins in hepatocellular carcinoma has been achieved, providing a basis for prognostic analysis of hepatocellular carcinoma and solving the problem of lack of prognostic predictive indicators for hepatocellular carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001094A_ABST
    Figure CN119001094A_ABST
Patent Text Reader

Abstract

The invention discloses a method for immunohistochemical detection of endotoxin in hepatocellular carcinoma, and relates to the technical field of immunohistochemical detection. The method comprises the following steps: (1) slicing: continuously slicing a pathological wax block, wherein the thickness is 4 microns; (2) baking the slices: baking the slices on a slice spreading machine at 37 DEG C for 30 minutes, and then baking the slices in an oven at 65 DEG C for 1 hour; (3) dewaxing: putting the slices into a slice rack, putting the slice rack into a xylene-containing box, and dewaxing for 3 times in each cylinder for 10 minutes; and (4) hydration: immersing the slices in absolute ethyl alcohol I for 5 minutes, 90% ethyl alcohol II for 3 minutes, 80% ethyl alcohol III for 3 minutes, and distilled water for 3 minutes * 2 cylinders. The invention discloses a method for immunohistochemical detection of endotoxin in hepatocellular carcinoma for the first time, solves the technical problem of immunohistochemical detection of endotoxin in hepatocellular carcinoma, and provides a method for level quantification of endotoxin in hepatocellular carcinoma. The hepatocellular carcinoma is lack of prognosis prediction indexes, and a foundation is laid for analyzing the influence of endotoxin on the prognosis of the hepatocellular carcinoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunohistochemical detection, in particular to a method for detecting endotoxin in hepatocellular carcinoma by immunohistochemical detection. Background Art

[0002] The liver possesses a dual blood supply system. In addition to nutrients and oxygen, it receives intestinal bacteria and their toxins through the portal vein, and antigen-rich blood through the hepatic artery. This blood, which passes through the sinusoids, is then taken up by a series of antigen-presenting cells and lymphocytes, which then initiate a complex immune response. Under normal conditions, the liver synthesizes various substances in the human body, converting toxic substances into non-toxic ones, playing a vital role in maintaining normal human life. The liver is also rich in immune cells, such as Kupffer cells, lymphocytes, and natural killer cells, which participate in the immune response. Together, they form the body's barrier to the outside world. Importantly, the liver maintains an anti-inflammatory or immune-tolerant state under normal conditions. The balance between immunity and tolerance is crucial for liver function. Because portal blood also transports a large number of foreign but harmless molecules (such as food antigens), the liver maintains immune tolerance to these macromolecules. However, when stimulated by harmful antigens, the liver can mount a rapid and robust immune response to eliminate them. Maintaining this balance and overall tissue health depends crucially on the well-defined division of labor and dynamic interaction among immune cell populations in the liver. The liver appears to be designed to detect, capture and eliminate bacteria, viruses and macromolecules. Based on the understanding of the liver's special functions, it is difficult for bacteria to break through this line of defense, and the liver has generally been considered a sterile organ in the past.

[0003] As our understanding of the interconnectedness of the gut-liver axis deepens, we are discovering that the intestinal microbiome, this "invisible organ," plays a crucial role in the development and progression of liver disease. Bacteria and their products have been shown to penetrate the weak intestinal barrier and enter the enterohepatic circulation. This ability is closely linked to bacterial toxins and the permeability of the intestinal wall, allowing higher levels of endotoxins and even bacteria to reach the liver via the portal vein. In addition to the portal system, the mesenteric lymphatic system also provides a nexus for pathogens, where they trigger adaptive immune responses and ultimately reach the liver. When this occurs, systemic infection does not occur, a phenomenon previously attributed to the liver's detoxification and immune filtration of the blood. A Yale University research team has discovered that enterococci can spontaneously metastasize to the lymph nodes, liver, and spleen. In mouse models, they have demonstrated that enterococci trigger the production of autoantibodies and inflammation, and these bacteria have also been detected in the livers of patients with autoimmune hepatitis.

[0004] With the development of 16S rDNA sequencing and metagenomic sequencing technologies, the composition of the liver microbiome has been re-evaluated. André et al. performed 16S rRNA sequencing on liver tissue from North American white-footed mice and found that Lactobacillus dominated at the genus level, followed by Bartonella, Staphylococcus, and Geminis. To verify the hypothesis that the source of liver bacteria is the gut microbiota, Joshua orally administered fluorescently labeled Porphyromonas gingivalis and then measured its abundance in the gut and liver. This hypothesis was confirmed, with P. gingivalis translocating to the liver. Linear regression analysis showed that, although P. gingivalis abundance decreased over time in the stomach and duodenum, its abundance in the liver remained stable. To test whether gut microbes exhibit selectivity, researchers transplanted fecal microbiota from specific pathogen-free donor mice into germ-free mice. Experimental data from fecal microbiota transplantation in germ-free mice suggest that the liver microbiome is selectively influenced by the gut. In the beta diversity analysis of 16S rDNA sequencing data, the human liver microbiome was more dispersed and aggregated than the intestinal tract; in addition, similar to the findings in mice, the abundance of Bacteroidetes was significantly higher in the liver than in the intestine, while that of Firmicutes was reduced. Similarly, alpha diversity analysis showed that the microbial richness in the human liver was significantly lower than that in the intestinal tract, and the evenness based on the Shannon and Simpson indices also decreased, which again was similar to the results found by the researchers in mice. The research data showed that there is a microbial community rich in Proteobacteria in the human liver, which is different from the characteristics of the intestinal tract. These evidences provide a reference for liver microbial research.

[0005] Due to the intrinsic characteristics of tumor tissue, tumor tissue may have a variety of intrinsic conditions that support bacterial invasion, survival, and growth. These conditions include: (1) the hypoxic environment inside the tumor, which is conducive to the growth of facultative and strict anaerobic bacteria; (2) the necrotic tissue inside the tumor provides sufficient nutrients (such as purine substances) for bacterial growth, which is conducive to bacterial reproduction. At the same time, the chemical signals appearing in the necrotic area also promote bacterial extravasation; (3) many new blood vessels appear around the tumor. These leaky vascular networks are easily used by circulating bacteria to enter the tissue; (4) due to the immune tolerance of the tumor, the colonized bacteria escape the host immune surveillance and reproduce easily. All of these factors may jointly contribute to the formation of the microbiome in the tumor. In fact, intratumoral bacteria have been reported to exist in many tumor types. There is evidence of the existence of intratumoral microorganisms in human tumor types such as melanoma, lung cancer, breast cancer, brain glioma, osteosarcoma, and ovarian cancer, whether located on the periphery of the tumor tissue or deep inside the tissue. These microorganisms may not only affect the growth and progression of the tumor, but also affect the treatment effect and the prognosis of the patient. Their role can no longer be ignored. Currently, there is little research on bacteria in hepatocellular carcinoma (HCC). There are no reports using immunohistochemistry to prove the presence of bacterial components in HCC. HCC lacks prognostic indicators, and conventional immunohistochemistry procedures cannot detect LPS expression. Therefore, we proposed an immunohistochemical method to detect endotoxins in HCC. Summary of the Invention

[0006] The purpose of the present invention is to provide a method for immunohistochemical detection of endotoxin in hepatocellular carcinoma to solve the problems raised by the above background technology.

[0007] To achieve the above object, the present invention provides the following technical solution: a method for immunohistochemical detection of endotoxin in hepatocellular carcinoma, comprising the following steps:

[0008] Step 1: Sectioning: Serial sections of pathological paraffin blocks with a thickness of 4 μm;

[0009] Step 2: Place the slices on a slide spreader and bake at 37°C for 30 minutes, then place in a 65°C oven for 1 hour.

[0010] Step 3, dewaxing: Place the slices in a slice rack and place them in a box containing xylene for dewaxing, 10 minutes per tank, for a total of 3 times;

[0011] Step 4, hydration: immerse the sections in anhydrous ethanol I for 5 min, 90% ethanol II for 3 min, 80% ethanol III for 3 min, and distilled water for 3 min × 2 tanks;

[0012] Step 5: Antigen retrieval: Add the prepared TRIS-EDTA to the cylinder containing the slices, boil water in the pressure cooker, and then place it in the cylinder. After the temperature rises to 120°C, continue for 3 minutes.

[0013] Step 6: After cooling naturally for 10 minutes, open the pressure cooker and rinse the slices with two cylinders of distilled water for 3 minutes each. Use an immunohistochemistry pen to circle the outer edge of the tissue.

[0014] Step 7: Block endogenous peroxidase: Add 3% hydrogen peroxide to the slices for blocking. Place the slices flat on a moist chamber filled with a small amount of distilled water and incubate in a dark oven at 37°C for 8 minutes. Filter the slices with distilled water twice, each for 3 minutes.

[0015] Step 8. Incubate with primary antibody: Prepare primary antibody (LPS, Hycult Biotech, Cat. No. 30443M1220) with primary antibody diluent (Anbiping). Add 50-100 μL of the prepared primary antibody to the tissue according to the size of the tissue. Place the tissue flat in a humidified chamber filled with a small amount of distilled water and incubate at 37°C for 35 min.

[0016] Step 9, wash the primary antibody: wash with PBST for 5 min × 3 times;

[0017] Step 10: Incubate with secondary antibody: add 50-100 μL of secondary antibody for both mouse and rabbit to the tissue and incubate in a 37°C oven for 10 min.

[0018] Step 11, washing secondary antibody: washing with PBST for 5 min × 3 times;

[0019] Step 12: Color development: Prepare the color development solution according to the DAB color development instructions (Roche, k27151), drop it on the tissue as needed and observe under a microscope. Adjust the staining time according to the depth of staining. Place the sections in distilled water to stop color development for 1 minute, and rinse with tap water for 2 minutes.

[0020] Step 13, counterstaining and reblueing: Place the sections into a jar containing Mayer's hematoxylin staining solution, slowly shake the sections and stain for 30 seconds, then rinse with tap water for 10 minutes;

[0021] Step 14, dehydration: soak the sections in 100% ethanol for 10 minutes x 2 tanks, and in xylene for 30 minutes x 2 tanks. This step is to make the slide background transparent;

[0022] Step 15: Use neutral gum to seal the slides;

[0023] Step 16: Microscopic examination, image acquisition, and quantitative analysis of immunohistochemistry results using Image J.

[0024] Preferably, in step 5, the pH of TRIS-EDTA is 8.0, and a high temperature and high pressure antigen retrieval method is used.

[0025] Preferably, in step 8, the primary antibody diluent is Ambiquinone, diluted at a ratio of 1:400, and the LPS primary antibody is from Hycult Biotech, product number 30443M1220.

[0026] Preferably, in step 10, the secondary antibody is Roche, with a ratio of k27081:k27082 of 1:1.

[0027] Preferably, in step 12, the color developing solution is prepared according to the DAB color development instructions (Roche, k27151).

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] The present invention discloses for the first time a method for immunohistochemical detection of endotoxins in hepatocellular carcinoma, which solves the technical difficulties of immunohistochemical detection of endotoxins in hepatocellular carcinoma and provides a method for quantifying the level of endotoxins in hepatocellular carcinoma. Hepatocellular carcinoma lacks prognostic prediction indicators, and the present invention lays the foundation for analyzing the impact of endotoxins on the prognosis of hepatocellular carcinoma.

[0030] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present invention will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 a. Schematic diagram of HE staining and immunohistochemistry (50 μm), including the location of LPS in cancerous tissue (indicated by red arrows) and non-cancerous tissue (indicated by black arrows); b. Schematic diagram of LPS immunohistochemistry of HepG2 cells from different batches.

[0032] Figure 2 a.LPS Low 、LPS High Schematic diagram of two groups of LPS IHC; b.LPS Low 、LPS High Schematic diagram of Kaplan-Meier survival analysis for the two groups. DETAILED DESCRIPTION

[0033] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0034] See also Figure 1 The present invention provides a method for immunohistochemically detecting endotoxin in hepatocellular carcinoma, comprising the following steps:

[0035] Step 1: Sectioning: Serial sections of pathological paraffin blocks with a thickness of 4 μm;

[0036] Step 2: Place the slices on a slide spreader and bake at 37°C for 30 minutes, then place in a 65°C oven for 1 hour.

[0037] Step 3, dewaxing: Place the slices in a slice rack and place them in a box containing xylene for dewaxing, 10 minutes per tank, for a total of 3 times;

[0038] Step 4, hydration: immerse the sections in anhydrous ethanol I for 5 min, 90% ethanol II for 3 min, 80% ethanol III for 3 min, and distilled water for 3 min × 2 tanks;

[0039] Step 5: Antigen retrieval: Add the prepared TRIS-EDTA (pH 8.0) to the cylinder containing the slices and use the high temperature and high pressure antigen retrieval method. After boiling water in the pressure cooker, add it and wait until the temperature rises to 120°C and continue for 3 minutes;

[0040] Step 6: After cooling naturally for 10 minutes, open the pressure cooker and rinse the slices with two cylinders of distilled water for 3 minutes each. Use an immunohistochemistry pen to circle the outer edge of the tissue.

[0041] Step 7: Block endogenous peroxidase: Add 3% hydrogen peroxide to the slices for blocking. Place the slices flat on a moist chamber filled with a small amount of distilled water and incubate in a dark oven at 37°C for 8 minutes. Filter the slices with distilled water twice, each for 3 minutes.

[0042] Step 8. Incubate with primary antibody: Prepare primary antibody (LPS, Hycult Biotech, Cat. No. 30443M1220) with primary antibody diluent (Anbiping), dilute at a ratio of 1:400 according to the size of the tissue, add 50-100 μL of the prepared primary antibody to the tissue, place it flat in a humidified chamber filled with a small amount of distilled water and incubate at 37°C for 35 min;

[0043] Step 9, wash the primary antibody: wash with PBST for 5 min × 3 times;

[0044] Step 10: Incubate with secondary antibody: add 50-100 μL of secondary antibody for both mouse and rabbit (Roche, k27081:k27082 in a 1:1 ratio) to the tissue and incubate in a 37°C oven for 10 min.

[0045] Step 11, washing secondary antibody: washing with PBST for 5 min × 3 times;

[0046] Step 12: Color development: Prepare the color development solution according to the DAB color development instructions (Roche, k27151), drop it on the tissue as needed and observe under a microscope. Adjust the staining time according to the depth of staining. Place the sections in distilled water to stop color development for 1 minute, and rinse with tap water for 2 minutes.

[0047] Step 13, counterstaining and reblueing: Place the sections into a jar containing Mayer's hematoxylin staining solution, slowly shake the sections and stain for 30 seconds, then rinse with tap water for 10 minutes;

[0048] Step 14, dehydration: soak the sections in 100% ethanol for 10 minutes x 2 tanks, and in xylene for 30 minutes x 2 tanks. This step is to make the slide background transparent;

[0049] Step 15: Use neutral gum to seal the slides;

[0050] Step 16: Microscopic examination, image acquisition, and quantitative analysis of immunohistochemistry results using Image J.

[0051] Example

[0052] We collected pathological paraffin blocks from 93 patients undergoing HCC surgery at the Second Affiliated Hospital of South China University of Technology between January 2017 and March 2021. Inclusion criteria were as follows: 1. Patients undergoing first-time HCC surgery; 2. Patients meeting ethical review criteria. Exclusion criteria were as follows: 1. Patients receiving chemoradiotherapy, chemotherapy, or immunotherapy before or after surgery; 2. Patients receiving antibiotics before the current hospitalization; and 3. Patients whose follow-up was lost. The entire study was approved by the Ethics Committee of the Second Affiliated Hospital of South China University of Technology (Ethics Approval No. K-2022-031-02).

[0053] Immunohistochemistry was used to identify LPS in the cell walls of Gram-negative bacteria and lipoteichoic acid (LTA) in Gram-positive bacteria. FISH with the bacteria-specific probe EUB338 was used to identify bacterial 16S rRNA components. Immunofluorescence was used to observe the localization of bacteria and immune cells. Further validation was performed by aseptically collecting fresh human hepatocellular carcinoma tissue and adjacent tissue from March 2021 to January 2023. Sequencing the V3-V4 region of 16S rDNA was used to identify differences in bacterial composition within HCC and adjacent tissues. Bacterial culture was then used to further identify evidence of viable bacteria in HCC.

[0054] LPS is a component of the cell wall of Gram-negative bacteria. For immunohistochemistry (IHC), we used paraffin sections from patients with appendicitis as a positive control for LPS, a bacterial component, and used PBS instead of the primary antibody against LPS as a blank control.

[0055] Appendicitis IHC showed LPS positive ( Figure 1-a). We found LPS-positive cohorts in 93 human HCC paraffin sections, of which 49.5% had a positive area >0.2%. LPS-positive tissues were present in both cancerous tissues (indicated by red arrows) and non-cancerous tissues (indicated by black arrows). LPS immunohistochemistry of sterile cultured HepG2 cells was used as a negative control, and no LPS-positive cells were found due to external interference such as experimental environment and experimental procedures. Figure 1 -b).

[0056] Table 1. Clinical characteristics of the HCC cohort

[0057]

[0058] *:P<0.05

[0059] Based on the cutoff of 0.2% of the total area by DAB positive immunohistochemistry, we found that LPS was present in 93 cases of HCC. Low 、LPS High There was a significant difference in LPS expression between the two cohorts (as shown in Table 1) (P < 0.05) (e.g. Figure 2 -a), Kaplan-Meier survival analysis showed that LPS High The median OS of the group was 95 weeks (95% CI 73.6-119 weeks), and the LPS Low The median OS of the two groups was 149 weeks (95% CI 91-207 weeks), and the difference between the two groups was significant (χ 2 =10.161, P = 0.001)(e.g. Figure 2 -b).

[0060] Patients' age, sex, survival or death status, recurrence status, tumor-node-metastasis (TNM) stage, and tissue grade were collected. Differences in survival or death status, recurrence status, TNM stage, and tissue grade were found between the two groups (Table 1) (P < 0.05). There were no differences in age or sex (P > 0.05).

[0061] The present invention discloses for the first time a method for immunohistochemical detection of endotoxins in hepatocellular carcinoma, which solves the technical difficulties of immunohistochemical detection of endotoxins in hepatocellular carcinoma and provides a method for quantifying the level of endotoxins in hepatocellular carcinoma. Hepatocellular carcinoma lacks prognostic prediction indicators, and the present invention lays the foundation for analyzing the impact of endotoxins on the prognosis of hepatocellular carcinoma.

[0062] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0063] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. Immunohistochemical method for detecting endotoxin in hepatocellular carcinoma. It is characterized in that The steps include: Step 1: Slice: Continuous slices of pathological wax blocks, thickness 4 μm; Step 2: Place the slices on a slide spreader and bake at 37°C for 30 minutes, then place in a 65°C oven for 1 hour. Step 3, dewaxing: put the slices into the slice rack, put them into the box containing xylene, and dewax them, 10 minutes per cylinder, 3 times in total; Step 4, hydration: immerse the slices in anhydrous ethanol I for 5 min, 90% ethanol II for 3 min, 80% ethanol III for 3 min, and distilled water for 3 min × 2 cylinders; Step 5, antigen repair: add the prepared TRIS-EDTA into the cylinder containing the slices, put it into the pressure cooker after boiling water, and continue for 3 minutes after the temperature rises to 120℃; Step 6: After cooling down for 10 minutes under natural conditions, open the pressure cooker and rinse the slices with 2 cylinders of distilled water, 3 minutes each cylinder, and circle the outer edge of the tissue with an immunohistochemistry pen; Step 7, blocking endogenous peroxidase: add 3% hydrogen peroxide to the slices for blocking, place them flat on a wet box filled with a small amount of distilled water, incubate in a dark oven at 37°C for 8 minutes, and rinse with 2 bottles of distilled water, each for 3 minutes; Step 8, incubate with primary antibody: prepare primary antibody with primary antibody diluent, add 50-100 μL of the prepared primary antibody to the tissue according to the size of the tissue, and place it flat on a wet box filled with a small amount of distilled water and incubate at 37°C for 35 minutes; Step 9, wash the primary antibody: wash with PBST for 5 min × 3 times; Step 10, incubate with secondary antibody: add 50-100 μL of secondary antibody for mice and rabbits to the tissue and incubate in a 37°C oven for 10 min; Step 11, washing secondary antibody: washing with PBST for 5 min × 3 times; Step 12, color development: prepare the color development solution according to the DAB color development instructions, drop it on the tissue as needed and observe under the microscope, adjust the staining time according to the depth of staining, put the slices in distilled water to stop color development for 1 minute, and rinse with tap water for 2 minutes; Step 13, re-staining and blueing: put the slices into a cylinder containing Mayer's hematoxylin staining solution, slowly shake the slices and stain for 30 seconds, and rinse with tap water for 10 minutes; Step 14, dehydration: soak the sections in 100% ethanol for 10 min × 2 tanks, and in xylene for 30 min × 2 tanks. This step is to make the slide background transparent; Step 15: Use neutral gum to seal the slide; Step 16: Microscopic examination, image acquisition, and quantitative analysis of immunohistochemistry results using Image J.

2. The method for detecting endotoxin in hepatocellular carcinoma by immunohistochemistry according to claim 1, Features: In step 5, the pH of TRIS-EDTA is 8.0, and a high temperature and high pressure antigen retrieval method is used.

3. The method for detecting endotoxin in hepatocellular carcinoma by immunohistochemistry according to claim 1, Features: In the step 8, the primary antibody diluent uses Anbiping and is diluted at a ratio of 1:

400.

4. The method for detecting endotoxin in hepatocellular carcinoma by immunohistochemistry according to claim 1, Features: In step 10, the secondary antibody used was Roche, with k27081:k27082 in a 1:1 configuration.